Chronic Kidney Disease Clinical Trial
Official title:
Evaluating the Role of Cystatin C and Creatinine as Markers of Renal Recovery in Critically Ill Patients After Acute Kidney Injury.
This is a cohort study in which patients who survive Acute Kidney Injury (AKI) during
intensive care unit (ICU) admission are recalled at 3-6 months and renal function tests are
performed.
The purpose of the study is describe renal function in AKI survivors at follow-up.
Additional aims are to determine how well admission values of renal function markers perform
as predictors of renal function at follow-up and whether estimates of renal function at
follow-up differ depending on which renal function marker is used.
Type of study: Cohort study with prospectively collected clinical data cross-matched with
local & national databases.
Source population: Patients suffering from AKI on a mixed intensive care unit, at the
Karolinska University Hospital, Solna.
Setting: Single centre, Central Intensive Care unit Karolinska University hospital, Solna,
Stockholm from September 2008 and May 2011.
Exposure: AKI on ICU and grade of AKI according to the RIFLE criteria Intervention: none
Outcome: Renal function 3 months after ICU discharge according to creatinine and Cystatin C
measurements.
Parameters: Co-morbidities, ICU diagnoses, disease severity score, daily physiological and
laboratory parameters, medications administered, interventions RRT (Renal replacement
therapy), mechanical intervention, inotropes, surgery.
Data is crossmatched with national registries including the Swedish cause of death register
(to obtain dates of death), the Swedish renal register (to obtain details of patients
receiving chronic dialysis and with pre-existing Chronic Kidney Disease (CKD) diagnoses. Data
is also cross matched with a large local ICU register (Clinisoft) to obtain physiological
parameters& intervention details. Clinisoft is also used to obtain risk of death for all ICU
patients and all AKI patients (from the source population). Ethical approval has been granted
by Stockholm Regional ethical review body (2008-408-32 2008/443-31/1-3, 2010/1780-31-2,
2011-408-32 and 2016-1801-32).
Aims:
1. Describe the incidence of renal dysfunction in terms of Glomerular filtration rate (GFR)
under 60ml/min/173m² at 3-6 months follow-up after AKI. According to serum Cystatin C
and Creatinine values.
2. Describe the incidence of Acute Kidney Disease (AKD) at 3 month follow-up.
3. Produce a predictive model using comorbidities and admission data to CKD (Chronic Kidney
Disease) and AKD 3-6 after AKI in intensive care patients.
4. Examine how estimated GFR using creatinine and Cystatin C differ from measured Iohexol
GFR at 6 month follow-up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
| Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
| Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
| Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
| Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
| Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
| Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
| Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
| Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
| Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
| Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
| Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
| Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
| Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |